Biocartis is an innovative commercial stage molecular testing company providing next generation solutions to researchers in oncology and infectious disease. Our global headquarters are in Mechelen, Belgium with a U.S. office located in Jersey City, New Jersey.
Our proprietary Idylla™ platform is a fully automated, real time system which offers highly-reliable molecular information from both tissue and plasma in virtually any lab setting. This is the first ever fully automated molecular testing system with a growing menu focused on oncology.
Globally, we have a presence in 70 countries and there are over 500 Idylla™ systems in place. We’re also working with a number of key industry partners as we develop a rapidly expanding test menu to meet and address growing needs in the oncology sector. These partnerships include an agreement with Amgen to validate our RAS tests for future use as a CDx for Vectibix®, which is the first fully human monoclonal anti-EGFR antibody approved by the FDA for the treatment of mCRC. In addition to our direct sales channels, the Idylla™ platform is also available in the U.S. through our national distribution partner Thermo Fisher Scientific.
As a company, our goal is to make molecular testing convenient and affordable while providing direct access to molecular testing, anywhere and anytime.
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.